The Technical Analyst
Xilio Therapeutics, Inc. [XLO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Xilio Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.38% $1.230
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 42.40 mill |
| EPS: | -2.78 |
| P/E: | -0.440 |
| Earnings Date: | Apr 01, 2024 |
| SharesOutstanding: | 34.47 mill |
| Avg Daily Volume: | 1.199 mill |
| RATING 2024-04-17 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.440 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.07x |
| Company: PE -0.440 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.169 (-4.93%) $-0.0607 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.143 - 1.317 ( +/- 7.07%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-02 | Gilead Sciences, Inc. | Buy | 485 250 | Common Stock |
| 2024-04-02 | Gilead Sciences, Inc. | Buy | 3 882 450 | Prefunded Warrants (right to buy) |
| 2024-03-27 | Gilead Sciences, Inc. | Sell | 0 | Common Stock |
| 2024-02-08 | Atlas Venture Fund Xi, L.p. | Sell | 733 | Common Stock |
| 2024-02-08 | Atlas Venture Fund Xi, L.p. | Sell | 267 | Common Stock |
| INSIDER POWER |
|---|
| 91.65 |
| Last 95 transactions |
| Buy: 18 066 351 | Sell: 51 747 162 |
Forecast:
16:00 - $1.230
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.230
Forecast 2: 16:00 - $1.230
Forecast 3: 16:00 - $1.230
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.230 (-5.38% ) |
| Volume | 0.437 mill |
| Avg. Vol. | 1.199 mill |
| % of Avg. Vol | 36.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For XLO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
XLO
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-04-01 16:05:00 - Press Release
Xilio Therapeutics Announces Pipeline And Business Updates And Fourth Quarter And Full Year 2023 Financial Results
On track with plans to initiate phase 2 trial for xtx101, a tumor-activated, fc-enhanced anti-ctla-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (mss crc) in the third quarter of 2024
2024-03-28 07:05:00 - Press Release
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for xtx301, a tumor-activated, il-12, and xtx101, a tumor-activated, fc-enhanced anti-ctla-4, and leveraging the company's promising research platform for tumor-activated bispecific and cell engager molecules
2024-03-28 07:00:00 - Press Release
Gilead And Xilio Announce Exclusive License Agreement For Tumor-activated Il-12 Program
Foster city, calif. & waltham, mass.--(business wire)--gilead sciences, inc. (nasdaq: gild) and xilio therapeutics, inc. (nasdaq: xlo) today announced an exclusive license agreement to develop and commercialize xilio's phase 1 tumor-activated il-12 program, xtx301. xilio therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies. the company is using its proprietary tumor-activation platform to build a pipeline of novel, tumor-act.
2024-02-28 16:01:00 - Press Release
Xilio Therapeutics To Participate In Novel Immuno-oncology Panel At Td Cowen 44th Annual Health Care Conference
Waltham, mass., feb. 28, 2024 (globe newswire) -- xilio therapeutics, inc. (nasdaq: xlo), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that renÉ russo, pharm.d., president and chief executive officer, will participate in the “novel immuno-oncology” panel discussion during the td cowen 44th annual health care conference on monday, march 4, 2024 at 10:30 am est.
2024-01-31 16:01:00 - Press Release
Xilio Therapeutics To Present At Guggenheim 6th Annual Biotechnology Conference
Waltham, mass., jan. 31, 2024 (globe newswire) -- xilio therapeutics, inc. (nasdaq: xlo), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that renÉ russo, pharm.d., president and chief executive officer, will participate in a fireside chat at the guggenheim 6th annual biotechnology conference on wednesday, february 7, 2024 at 12:30 pm est.
Latest News
2024-04-16 10:16:16 - Zacks Investment Research
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.
2024-03-31 06:26:00 - PennyStocks
Sizing Your Penny Stocks Position, 3 Tips
Sizing positions correctly is a cornerstone of successful investing, especially when dealing with penny stocks. The unique nature of penny stocks, with their potential for substantial gains, requires a nuanced approach to position sizing.
2024-03-28 11:10:38 - InvestorPlace
Why Is Xilio Therapeutics (XLO) Stock up 168% Today?
Xilio Therapeutics (NASDAQ: XLO ) stock is rocketing higher on Thursday after the clinical-stage biotechnology company signed an exclusive license agreement with Gilead Sciences (NASDAQ: GILD ). This agreement has Gilead taking over the development and commercialization responsibilities of Xilio Therapeutics' XTX301.
2024-01-31 16:01:00 - GlobeNewsWire
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 pm EST.
2023-10-31 09:15:00 - GlobeNewsWire
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and webcast on November 6, 2023 at 8:00 a.m. ET to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, which will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023.
2023-09-05 07:30:00 - GlobeNewsWire
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 2:55 pm EST.
2023-02-27 07:30:00 - GlobeNewsWire
Xilio Therapeutics to Present at Upcoming Investor Conferences
WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced its participation in the following upcoming investor conferences:
2023-02-16 07:30:00 - GlobeNewsWire
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit
WALTHAM, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in Citi's 2023 Virtual Oncology Leadership Summit on Thursday, February 23, 2023, at 9:00 a.m. ET.
2023-02-02 07:30:00 - GlobeNewsWire
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023, at 3:55 p.m. ET in New York.
2022-11-04 07:30:00 - GlobeNewsWire
Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next' Summit
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will participate in a virtual fireside chat at the Cowen 6th Annual IO Next Summit on Friday, November 11, 2022, at 1:40 p.m. ET.